Literature DB >> 15957520

The influence of sex hormones on cytokines in multiple sclerosis and experimental autoimmune encephalomyelitis: a review.

Hans H L P van den Broek1, Jan G M C Damoiseaux, Marc H De Baets, Raymond M M Hupperts.   

Abstract

The female predominance of multiple sclerosis (MS) has suggested that hormonal differences between the sexes must confer some protective effect on males or enhance the susceptibility of females to this disease. There has been evidence that gonadal hormones can modulate the immune response regulated by antigen presenting cells and T cells. These cells control the immune response by the production of interacting pro- and anti-inflammatory cytokines. The first include the acute phase pro-inflammatory cytokines of the innate immune response as well as the T-helper 1 (Th1) cytokines, while the later contain the Th2 cytokines as well as the suppressor cytokines. There is some evidence that MS and experimental autoimmune encephalitis (EAE) are Th1 cell-mediated diseases. For this reason many studies have been done to influence the pro-inflammatory cytokine production of these Th1 cells in favour of an anti-inflammatory immune response as mediated by Th2 cells. However the role of the regulatory T cells in this context is not clearly understood. Here we review the studies concerning the role of sex hormones on the cytokine production in relation to the disease course of MS and EAE and in particular in the light of the recent revival of the regulatory T cells and their suppressive cytokines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15957520     DOI: 10.1191/1352458505ms1174rr

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  9 in total

Review 1.  Illuminating vitamin D effects on B cells--the multiple sclerosis perspective.

Authors:  Linda Rolf; Anne-Hilde Muris; Raymond Hupperts; Jan Damoiseaux
Journal:  Immunology       Date:  2016-02-02       Impact factor: 7.397

2.  Strikingly higher interleukin (IL)-1alpha, IL-1beta and soluble interleukin-1 receptor antagonist (sIL-1RA) but similar IL-2, sIL-2R, IL-3, IL-4, IL-6, sIL-6R, IL-10, tumour necrosis factor (TNF)-alpha, transforming growth factor (TGF)-beta and interferon IFN-gamma urine levels in healthy females compared to healthy males: protection against urinary tract injury?

Authors:  M Sadeghi; V Daniel; C Naujokat; R Weimer; G Opelz
Journal:  Clin Exp Immunol       Date:  2005-11       Impact factor: 4.330

3.  The relation between peptide hormones and sex hormone in patients with multiple sclerosis.

Authors:  Elham Eftekhari; Masoud Etemadifar; Ali Ebrahimi; Shahrzad Baradaran
Journal:  Iran J Neurol       Date:  2013

4.  A multicentric pharmacovigilance study: collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients.

Authors:  Agnese Gugliandolo; Federica Longo; Maria Giovanna Marrosu; Giovanni Luigi Mancardi; Ilaria Gandoglia; Maurizio Melis; Fabrizio Lo Giudice; Placido Bramanti; Emanuela Mazzon
Journal:  Ther Clin Risk Manag       Date:  2018-09-26       Impact factor: 2.423

Review 5.  The IL-2 - IL-2 receptor pathway: Key to understanding multiple sclerosis.

Authors:  Daphne Peerlings; Max Mimpen; Jan Damoiseaux
Journal:  J Transl Autoimmun       Date:  2021-09-21

Review 6.  Gender and sex hormones in multiple sclerosis pathology and therapy.

Authors:  Arnaud Nicot
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

7.  Estriol and progesterone: a new role for sex hormones.

Authors:  Sanja Draca
Journal:  Int J Biomed Sci       Date:  2006-12

8.  A sex-specific metabolite identified in a marine invertebrate utilizing phosphorus-31 nuclear magnetic resonance.

Authors:  Robert A Kleps; Terrell C Myers; Romuald N Lipcius; Thomas O Henderson
Journal:  PLoS One       Date:  2007-08-22       Impact factor: 3.240

9.  Epidemiology of necrotizing meningoencephalitis in Pug dogs.

Authors:  J M Levine; G T Fosgate; B Porter; S J Schatzberg; K Greer
Journal:  J Vet Intern Med       Date:  2008 Jul-Aug       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.